MEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
Industry, Sector and Symbol
Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:MD
CUSIP58502B10
Phone954-384-0175
Debt
Debt-to-Equity Ratio0.60%
Current Ratio1.18%
Quick Ratio1.18%
Price-To-Earnings
Trailing P/E Ratio16.20
Forward P/E Ratio12.79
P/E Growth1.3
Sales & Book Value
Annual Sales$3.46 billion
Price / Sales1.38
Cash Flow$4.20 per share
Price / Cash12.15
Book Value$32.74 per share
Price / Book1.56
Profitability
EPS (Most Recent Fiscal Year)$3.15
Net Income$320.37 million
Net Margins9.26%
Return on Equity10.10%
Return on Assets5.23%
Miscellaneous
Employees7,675
Outstanding Shares93,800,000
MEDNAX (NYSE:MD) Frequently Asked Questions
What is MEDNAX's stock symbol?
MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."
How were MEDNAX's earnings last quarter?
MEDNAX Inc (NYSE:MD) posted its earnings results on Thursday, February, 8th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.83 by $0.04. The firm had revenue of $910.82 million for the quarter, compared to analyst estimates of $884.55 million. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. MEDNAX's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period last year, the company earned $1.00 earnings per share. View MEDNAX's Earnings History.
When is MEDNAX's next earnings date?
What guidance has MEDNAX issued on next quarter's earnings?
MEDNAX issued an update on its first quarter earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of $0.84-0.89 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.79.
What price target have analysts set for MD?
13 brokerages have issued twelve-month price objectives for MEDNAX's stock. Their forecasts range from $47.00 to $62.00. On average, they expect MEDNAX's share price to reach $55.3333 in the next twelve months. View Analyst Ratings for MEDNAX.
Who are some of MEDNAX's key competitors?
Some companies that are related to MEDNAX include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Eurofins Scientific (ERFSF), BeiGene (BGNE), WellCare (WCG), bluebird bio (BLUE), STERIS (STE), Seattle Genetics (SGEN), Bio-Rad Laboratories (BIO), SAGE Therapeutics (SAGE), Valeant Pharmaceuticals International (VRX), AveXis (AVXS), Alkermes (ALKS), Neurocrine Biosciences (NBIX), West Pharmaceutical Services (WST), ICON (ICLR), Stada Arzneimittel (STDAF) and Dexcom (DXCM).
Who are MEDNAX's key executives?
MEDNAX's management team includes the folowing people:
- Cesar L. Alvarez, Chairman of the Board (Age 69)
- Joseph M. Calabro, President, Chief Operating Officer (Age 56)
- Roger J. Medel M.D., Chief Executive Officer, Director (Age 70)
- Vivian Lopez-Blanco, Chief Financial Officer, Treasurer (Age 59)
- David A. Clark, President - MEDNAX National Medical Group Division (Age 50)
- John C. Pepia, Senior Vice President, Chief Accounting Officer (Age 54)
- Dominic J. Andreano, Senior Vice President, General Counsel, Secretary (Age 48)
- Manuel Kadre, Lead Independent Director (Age 51)
- Karey D. Barker, Independent Director (Age 49)
- Waldemar A. Carlo M.D., Independent Director (Age 64)
Has MEDNAX been receiving favorable news coverage?
Press coverage about MD stock has trended positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MEDNAX earned a news impact score of 0.29 on Accern's scale. They also gave headlines about the company an impact score of 46.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of MEDNAX?
Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEDNAX's stock price today?
One share of MD stock can currently be purchased for approximately $51.03.
How big of a company is MEDNAX?
MEDNAX has a market capitalization of $4.88 billion and generates $3.46 billion in revenue each year. The company earns $320.37 million in net income (profit) each year or $3.15 on an earnings per share basis. MEDNAX employs 7,675 workers across the globe.
How can I contact MEDNAX?
MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]
MarketBeat Community Rating for MEDNAX (MD)
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.
MEDNAX (NYSE:MD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for MEDNAX in the last 12 months. Their average twelve-month price target is $55.3333, suggesting that the stock has a possible upside of 8.43%. The high price target for MD is $62.00 and the low price target for MD is $47.00. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.15 | 2.17 | 2.17 | 2.08 |
| Ratings Breakdown: | 1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $55.3333 | $55.1818 | $53.8182 | $55.4444 |
| Price Target Upside: | 8.43% upside | 3.78% downside | 2.45% upside | 31.11% upside |
MEDNAX (NYSE:MD) Consensus Price Target History
MEDNAX (NYSE:MD) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
MEDNAX (NYSE:MD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
MEDNAX (NYSE MD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 98.53%
MEDNAX (NYSE MD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/13/2018 | John C Pepia | Insider | Sell | 3,000 | $58.35 | $175,050.00 | 39,716 |  |
| 12/12/2017 | John C Pepia | Insider | Sell | 3,000 | $51.58 | $154,740.00 | 35,569 | |
| 11/3/2017 | Cesar L Alvarez | Director | Sell | 10,668 | $42.59 | $454,350.12 | 44,215 | |
| 9/12/2017 | John C Pepia | Insider | Sell | 3,000 | $42.85 | $128,550.00 | 35,569 | |
| 6/14/2017 | Md Pascal J Goldschmidt | Director | Sell | 1,969 | $57.57 | $113,355.33 | 18,072 | |
| 6/1/2017 | Joseph M Calabro | Insider | Sell | 23,327 | $55.00 | $1,282,985.00 | 296,379 | |
| 5/5/2017 | Manuel Kadre | Director | Buy | 21,704 | $55.79 | $1,210,866.16 | 111,255 | |
| 5/5/2017 | Vivian Lopez-Blanco | CFO | Sell | 7,778 | $55.82 | $434,167.96 | 51,319 | |
| 3/16/2017 | Robert Irwin Valliant | Director | Sell | 5,200 | $1.10 | $5,720.00 | | |
| 2/23/2017 | Enrique Sosa | Director | Sell | 10,668 | $69.65 | $743,026.20 | 21,923 | |
| 2/17/2017 | Vivian Lopez-Blanco | CFO | Sell | 15,164 | $70.01 | $1,061,631.64 | 59,097 | |
| 2/16/2017 | Dominic J Andreano | SVP | Sell | 6,000 | $69.59 | $417,540.00 | 30,746 | |
| 2/16/2017 | John C Pepia | Insider | Sell | 2,500 | $69.58 | $173,950.00 | 31,025 | |
| 2/16/2017 | Paul G Gabos | Director | Sell | 21,336 | $69.63 | $1,485,625.68 | 21,923 | |
| 2/10/2017 | Md Pascal J Goldschmidt | Director | Sell | 25,294 | $67.82 | $1,715,439.08 | 14,173 | |
| 2/9/2017 | Md Carlo A Waldemar | Director | Sell | 5,334 | $67.90 | $362,178.60 | 16,589 | |
| 1/17/2017 | Vivian Lopez-Blanco | CFO | Sell | 10,000 | $70.95 | $709,500.00 | 74,261 | |
| 12/7/2016 | Md Pascal J Goldschmidt | Director | Buy | 2,100 | $66.52 | $139,692.00 | 13,355 | |
| 9/14/2016 | Md Pascal J Goldschmidt | Director | Sell | 1,500 | $65.01 | $97,515.00 | 12,755 | |
| 6/13/2016 | Dominic J Andreano | SVP | Sell | 3,922 | $68.80 | $269,833.60 | 24,746 | |
| 6/8/2016 | Md Carlo A Waldemar | Director | Sell | 5,334 | $70.50 | $376,047.00 | 16,589 | |
| 6/7/2016 | Karl B Wagner | Insider | Sell | 27,482 | $68.45 | $1,881,142.90 | 105,932 | |
| 6/1/2016 | Joseph M Calabro | COO | Sell | 28,347 | $67.78 | $1,921,359.66 | 253,882 | |
| 6/1/2016 | Michael D Stanley | Insider | Sell | 14,778 | $67.78 | $1,001,652.84 | 49,266 | |
| 5/16/2016 | Dominic J Andreano | SVP | Sell | 3,000 | $68.53 | $205,590.00 | 21,313 | |
| 5/2/2016 | Vivian Lopez-Blanco | CFO | Sell | 9,350 | $71.22 | $665,907.00 | 64,083 | |
| 3/11/2016 | Md Pascal J Goldschmidt | Director | Sell | 3,100 | $65.00 | $201,500.00 | 12,479 | |
| 2/29/2016 | Paul G Gabos | Director | Sell | 10,668 | $67.15 | $716,356.20 | 20,047 | |
| 12/11/2015 | Md Pascal J. Goldschmidt | Director | Sell | 5,250 | $70.99 | $372,697.50 | 9,379 | |
| 9/8/2015 | Cesar L. Alvarez | Director | Sell | 10,668 | $81.00 | $864,108.00 | 29,379 | |
| 8/27/2015 | Roger Md Medel | CEO | Sell | 100,000 | $80.27 | $8,027,000.00 | 1,199,708 | |
| 6/8/2015 | Karl B Wagner | Insider | Sell | 37,820 | $70.28 | $2,657,989.60 | | |
| 6/3/2015 | Joseph M Calabro | COO | Sell | 108,071 | $70.51 | $7,620,086.21 | | |
| 3/9/2015 | Md Pascal J Goldschmidt | Director | Sell | 8,500 | $71.25 | $605,625.00 | | |
| 2/26/2015 | Roger Md Medel | CEO | Sell | 100,000 | $71.61 | $7,161,000.00 | | |
| 2/20/2015 | Md Carlo A Waldemar | Director | Sell | 10,668 | $71.50 | $762,762.00 | | |
| 2/6/2015 | Dominic J Andreano | SVP | Sell | 3,200 | $70.75 | $226,400.00 | | |
| 2/6/2015 | Vivian Lopez-Blanco | CFO | Sell | 8,250 | $69.95 | $577,087.50 | | |
| 2/2/2015 | Paul G Gabos | Director | Sell | 17,584 | $68.07 | $1,196,942.88 | | |
| 1/30/2015 | William C Hawk | COO | Sell | 3,598 | $68.50 | $246,463.00 | | |
| 11/14/2014 | Roger Md Medel | CEO | Sell | 51,290 | $62.59 | $3,210,241.10 | | |
| 11/13/2014 | Roger Md Medel | CEO | Sell | 63,440 | $62.55 | $3,968,172.00 | | |
| 11/7/2014 | Roger Md Medel | CEO | Sell | 128,833 | $62.60 | $8,064,945.80 | | |
| 11/5/2014 | Roger Md Medel | CEO | Sell | 169,845 | $62.60 | $10,632,297.00 | | |
| 11/4/2014 | Roger Md Medel | CEO | Sell | 15,052 | $62.52 | $941,051.04 | | |
| 11/3/2014 | Roger Md Medel | CEO | Sell | 10,881 | $62.52 | $680,280.12 | | |
| 10/31/2014 | Roger Md Medel | CEO | Sell | 61,592 | $62.58 | $3,854,427.36 | | |
| 10/30/2014 | Karl B Wagner | Insider | Sell | 40,000 | $62.50 | $2,500,000.00 | | |
| 10/30/2014 | Vivian Lopez-Blanco | CFO | Sell | 8,800 | $60.00 | $528,000.00 | | |
| 7/30/2014 | Karl B Wagner | Insider | Sell | 80,000 | $60.00 | $4,800,000.00 | | |
| 6/10/2014 | Dominic J Andreano | SVP | Sell | 2,252 | $58.48 | $131,696.96 | | |
| 6/6/2014 | Karl B Wagner | Insider | Sell | 44,596 | $58.53 | $2,610,203.88 | | |
| 6/5/2014 | William C Hawk | COO | Sell | 6,911 | $57.66 | $398,488.26 | | |
| 6/2/2014 | David A Clark | COO | Sell | 16,230 | $57.00 | $925,110.00 | | |
| 6/2/2014 | Michael D Stanley | Insider | Sell | 18,006 | $57.00 | $1,026,342.00 | | |
| 5/9/2014 | Karl Wagner | Insider | Sell | 79,524 | $57.09 | $4,540,025.16 | 150,498 | |
| 5/9/2014 | Md Pascal Goldschmidt | Director | Sell | 30,000 | $57.11 | $1,713,300.00 | 5,350 | |
| 5/8/2014 | Joseph Calabro | COO | Sell | 137,500 | $57.06 | $7,845,750.00 | 226,542 | |
| 2/20/2014 | Dominic Andreano | SVP | Sell | 3,000 | $61.00 | $183,000.00 | 16,135 | |
| 2/10/2014 | Joseph Calabro | COO | Sell | 150,000 | $55.55 | $8,332,500.00 | 226,542 | |
| 2/10/2014 | Md Carlo Waldemar | Director | Sell | 10,668 | $55.40 | $591,007.20 | 5,350 | |
| 11/7/2013 | Enrique Sosa | Director | Sell | 5,334 | $107.00 | $570,738.00 | 2,675 | |
| 11/7/2013 | Karl Wagner | Insider | Sell | 1,800 | $107.60 | $193,680.00 | 75,249 | |
| 9/11/2013 | William C Hawk | COO | Sell | 3,162 | $100.62 | $318,160.44 | | |
| 9/10/2013 | Dominic J Andreano | SVP | Sell | 3,718 | $99.63 | $370,424.34 | | |
| 8/7/2013 | Karl Wagner | Insider | Sell | 25,000 | $98.01 | $2,450,250.00 | 75,249 | |
| 8/2/2013 | Joseph M Calabro | COO | Sell | 36,154 | $98.57 | $3,563,699.78 | | |
| 6/3/2013 | David A Clark | COO | Sell | 8,645 | $91.01 | $786,781.45 | | |
| 6/3/2013 | Michael D Stanley | Insider | Sell | 8,906 | $91.01 | $810,535.06 | | |
(Data available from 1/1/2013 forward)
MEDNAX (NYSE MD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | MEDNAX 2018 First Quarter Conference Call/Webcast Scheduled for Monday, May 7, 2018
finance.yahoo.com - April 20 at 4:10 PM |
| THE LIST: Legal battles shaking up Charlotte’s largest physician groups
finance.yahoo.com - April 20 at 10:08 AM |
 | Comparing MEDNAX (MD) and Encompass Health (EHC)
www.americanbankingnews.com - April 19 at 9:42 AM |
| MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE
finance.yahoo.com - April 18 at 4:18 PM |
| MEDNAX Inc (MD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 1:34 PM |
| Head-To-Head Comparison: MEDNAX (MD) vs. Magellan Health (MGLN)
www.americanbankingnews.com - April 18 at 3:20 AM |
| $904.13 Million in Sales Expected for MEDNAX Inc (MD) This Quarter
www.americanbankingnews.com - April 16 at 2:37 AM |
| MEDNAX (MD) and Magellan Health (MGLN) Critical Survey
www.americanbankingnews.com - April 15 at 11:15 AM |
| MEDNAX (MD) Given a $46.00 Price Target at Jefferies Group
www.americanbankingnews.com - April 15 at 9:45 AM |
| Zacks: Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.85 Per Share
www.americanbankingnews.com - April 14 at 5:09 PM |
| Analyzing Encompass Health (EHC) & MEDNAX (MD)
www.americanbankingnews.com - April 13 at 1:07 AM |
| Edited Transcript of MD presentation 6-Mar-17 1:40pm GMT
finance.yahoo.com - April 12 at 10:52 AM |
| MEDNAX (MD) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:58 AM |
| MedData’s New Patient Financial Platform Solves Inefficient, Costly Revenue Cycle Challenges
finance.yahoo.com - April 10 at 10:20 AM |
| Financial Contrast: Encompass Health (EHC) & MEDNAX (MD)
www.americanbankingnews.com - April 10 at 5:29 AM |
| Analyzing MEDNAX (MD) and Magellan Health (MGLN)
www.americanbankingnews.com - April 8 at 1:27 PM |
| MEDNAX (MD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:32 PM |
| Southeast Anesthesiology: ‘Facts will speak’ in lawsuit against Atrium Health
finance.yahoo.com - April 6 at 10:33 AM |
| MEDNAX in Collaboration with Memorial Regional Hospital Earns National Accreditation for Adult Congenital Heart Program
finance.yahoo.com - April 6 at 10:33 AM |
| Head-To-Head Survey: MEDNAX (MD) and Magellan Health (MGLN)
www.americanbankingnews.com - April 3 at 1:26 PM |
| MEDNAX (MD) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - April 3 at 12:11 PM |
| Head to Head Comparison: Magellan Health (MGLN) & MEDNAX (MD)
www.americanbankingnews.com - April 3 at 9:20 AM |
 | BRIEF-MEDNAX Announces Acquisition Of Pediatric Urology Practice In South Florida
www.reuters.com - April 2 at 10:23 AM |
 | Mednax acquires medical practice with 3 South Florida offices
www.bizjournals.com - April 2 at 10:23 AM |
 | MEDNAX (MD) Reports Acquisition of Pediatric Urology Practice in South Florida
www.streetinsider.com - April 2 at 10:23 AM |
 | MEDNAX acquires Pediatric Urology practice in South Florida
seekingalpha.com - April 2 at 10:23 AM |
| MEDNAX Inc (MD) Expected to Post Quarterly Sales of $905.91 Million
www.americanbankingnews.com - March 30 at 2:10 AM |
| MEDNAX Sees Unusually Large Options Volume (MD)
www.americanbankingnews.com - March 29 at 6:54 AM |
| Critical Analysis: Tabula Rasa HealthCare (TRHC) versus MEDNAX (MD)
www.americanbankingnews.com - March 28 at 5:40 PM |
 | Credit Suisse Takes Neutral Stance On Mednax, Says Buyout Value Reflected In Share Price
www.msn.com - March 27 at 4:04 PM |
| MEDNAX Announces Expansion of Radiology Practices
finance.yahoo.com - March 27 at 10:22 AM |
| MEDNAX (MD) Now Covered by Analysts at Credit Suisse Group
www.americanbankingnews.com - March 27 at 8:45 AM |
| MEDNAX (MD) PT Set at $50.00 by Jefferies Group
www.americanbankingnews.com - March 25 at 12:14 PM |
| MEDNAX Inc (MD) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 1:50 PM |
| BRIEF-Mednax Says CEO Roger Medel's Total Compensation For 2017 Was $7.4 Mln Versus $7.8 Mln In 2016
www.reuters.com - March 24 at 10:14 AM |
| MEDNAX (MD) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 21 at 8:54 PM |
| BRIEF-Mednax Announces Acquisition Of Pediatric Ophthalmology Practice In Washington
www.reuters.com - March 21 at 4:00 PM |
| MEDNAX Announces Acquisition of Pediatric Ophthalmology Practice in Washington
finance.yahoo.com - March 21 at 11:09 AM |
| Should Value Investors Pick MEDNAX (MD) Stock?
finance.yahoo.com - March 21 at 11:09 AM |
| MEDNAX (MD) Given a $58.00 Price Target at Jefferies Group
www.americanbankingnews.com - March 17 at 4:28 PM |
| [$$] Medical Wars
finance.yahoo.com - March 17 at 10:10 AM |
| John C. Pepia Sells 3,000 Shares of MEDNAX Inc (MD) Stock
www.americanbankingnews.com - March 14 at 7:49 PM |
| MEDNAX (MD) Upgraded by TheStreet to "B"
www.americanbankingnews.com - March 14 at 7:20 AM |
| Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.84 Per Share
www.americanbankingnews.com - March 11 at 1:18 PM |
| What Analysts Recommend for American Renal Associates Holdings
finance.yahoo.com - March 9 at 4:57 PM |
| Veeva Systems Rides on Strong Q4 & Cloud-Based Applications
finance.yahoo.com - March 8 at 10:23 AM |
| Cerner-Centrus Health to Collaborate, HealtheIntent in Focus
finance.yahoo.com - March 7 at 4:50 PM |
| The Manufacturers Life Insurance Company Acquires 17,163 Shares of MEDNAX Inc (MD)
www.americanbankingnews.com - March 6 at 3:12 PM |
| Cerner Collaborates With Salesforce, Focuses on AI Trends
www.msn.com - March 6 at 9:51 AM |
| Bank of New York Mellon Corp Sells 31,948 Shares of MEDNAX Inc (MD)
www.americanbankingnews.com - March 6 at 4:54 AM |
MEDNAX (NYSE:MD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MEDNAX (NYSE:MD) Income Statement, Balance Sheet and Cash Flow Statement
MEDNAX (NYSE MD) Stock Chart for Saturday, April, 21, 2018
Loading chart…
